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Abstract
Background: Multiple sclerosis is a chronic inflammatory disease of the central nervous system
with a pronounced neurodegenerative component. It has been suggested that novel treatment
options are needed that target both aspects of the disease. Evidence from basic and clinical studies
suggests that testosterone has an immunomodulatory as well as a potential neuroprotective effect
that could be beneficial in MS.
Methods: Ten male MS patients were treated with 10 g of gel containing 100 mg of testosterone
in a cross-over design (6 month observation period followed by 12 months of treatment). Blood
samples were obtained at three-month intervals during the observation and the treatment period.
Isolated blood peripheral mononuclear cells (PBMCs) were used to examine lymphocyte
subpopulation composition by flow cytometry and ex vivo protein production of cytokines (IL-2,
IFNγ, TNFα, IL-17, IL-10, IL-12p40, TGFβ1) and growth factors (brain-derived neurotrophic factor
BDNF, platelet-derived growth factor PDGF-BB, nerve growth factor NGF, and ciliary
neurotrophic factor CNTF). Delayed type hypersensitivity (DTH) skin recall tests were obtained
before and during treatment as an in vivo functional immune measure.
Results: Testosterone treatment significantly reduced DTH recall responses and induced a shift
in peripheral lymphocyte composition by decreasing CD4+ T cell percentage and increasing NK
cells. In addition, PBMC production of IL-2 was significantly decreased while TGFβ1 production was
increased. Furthermore, PBMCs obtained during the treatment period produced significantly more
BDNF and PDGF-BB.
Conclusion: These results are consistent with an immunomodulatory effect of testosterone
treatment in MS. In addition, increased production of BDNF and PDGF-BB suggests a potential
neuroprotective effect.
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Background
Multiple sclerosis (MS) has been considered a putative T
cell mediated autoimmune disease. However, it is becom-
ing increasingly clear that its pathology is far more com-
plicated and is characterized by both an inflammatory
component as well as a neurodegenerative process [1]. To
date, the relationship between inflammation and the neu-
rodegeneration in MS is unclear. Nevertheless, it is cur-
rently thought that potential new treatments should
ideally have anti-inflammatory as well as neuroprotective
properties [2].
Numerous models of autoimmune diseases including
experimental autoimmune encephalomyelitis (EAE), dia-
betes in nonobese mice, thyroiditis, and adjuvant arthritis
have been shown to be worsened by castration of male
animals [3-8]. Furthermore, testosterone treatment amel-
iorates EAE [9]. These protective effects are thought to be
mediated by testosterone's immunomodulatory proper-
ties such as decreasing the production of pro-inflamma-
tory cytokines TNFα and IL-1β by macrophages [10] and
monocytes [11] as well as increasing production of the
anti-inflammatory cytokine IL-10 by T cells [12].
In addition, evidence supporting a neuroprotective effect
of testosterone has been found in a variety of neurological
diseases as well as in the cognitive decline associated with
normal aging [13]. Testosterone is converted to estrogen
in the brain by aromatase, and the neuroprotective prop-
erties of testosterone treatment in vivo may be due at least
in part to this conversion. However, several in vitro studies
have shown that testosterone can also be more directly
neuroprotective [14]. Testosterone has been shown to
protect spinal cord neurons in culture from glutamate-
mediated toxicity, as well as to induce neuronal differen-
tiation and increase neurite outgrowth [15]. Testosterone
treatment also protected cultured neurons against beta-
amyloid toxicity induced cell death [16].
While CNS infiltrating immune cells were once thought to
always be deleterious, it has since been established that
they have the potential to be beneficial under certain con-
ditions, since neurotrophic factors have been detected in
peripheral blood mononuclear cells (PBMCs) [17].
Indeed, production of the neurotrophic factors BDNF and
NT-3 by immune cells has been shown to accompany bet-
ter recovery from spinal cord injury [18], and the produc-
tion of neurotrophic factors by immune cells has been
hypothesized as a potential means of neuroprotection in
MS [19].
Recently, a pilot clinical trial using testosterone to treat 10
male MS patients was completed [20]. In these patients,
cognitive function improved and the brain atrophy rate
was significantly slowed. Here, immunomodulatory
effects of testosterone treatment as well as its ability to
induce neurotrophic growth factor production in PBMCs
were examined in these patients to explore a potential
novel pathway underlying testosterone's beneficial effects.
Methods
Subjects
Ten men (mean age 46, range 29–61) who met Poser cri-
teria for clinically definite relapsing-remitting (RR) MS,
were not currently receiving disease modifying treatment
and had a mean Expanded Disability Status Score (EDSS)
of 2.0 (range 1.5–2.5) were studied. A six month pretreat-
ment observation period (month -6 to 0) was followed by
twelve months (months 1 to 12) of treatment with 10 g of
gel containing 100 mg of testosterone (AndroGel®)
applied to the upper arms once per day. Treatment
increased circulating testosterone levels from the lower
normal range to the higher range of normal, with average
increases of 50% [20].
Every three months clinical examinations were done and
blood was drawn to collect PBMCs. The protocol was
approved by the UCLA Human Subjects Protection Com-
mittee and all patients provided written informed consent
prior to enrollment in the study.
Delayed type hypersensitivity (DTH) test
Delayed type hypersensitivity (DTH) recall responses to
tetanus (Tetanus Toxoid; Wyeth Laboratories, Marietta,
PA) were assessed at two time points: once in the pretreat-
ment period at study month 0 and once in the middle of
the treatment period at study month 6, as described [21].
PBMC phenotyping and ex vivo stimulation
Cryopreserved PBMCs collected every three months
throughout the pretreatment and treatment periods were
thawed and analyzed simultaneously for every patient.
PBMC subpopulations before (month 0) and at the end of
treatment (month 12) were determined by flow cytome-
try. One aliquot of cells was stained for cell surface mark-
ers with a panel of conjugated Abs, including CD3 (FITC),
CD64 (FITC), CD14 (PE), CD4 (PE), CD8 (PE), CD16+56
(PE), CD45 (PerCP) and CD19 (Per-CP) (BD Bioscience)
to determine subpopulations.
For ex vivo protein production, PBMCs were cultured at 1
× 105 cells/well with either (1) anti-CD3 (1 μg/ml; Sigma-
Aldrich, St. Louis, MO) and anti-CD28 (2.5 μg/ml; Sigma-
Aldrich), or (2) PHA (5 μg/ml; Sigma-Aldrich) or (3)
media alone, as described [22] Protein levels were assayed
in supernatants at 48 h and 72 h using SearchLight multi-
plex assays for growth factors (brain-derived neurotrophic
factor BDNF, platelet-derived growth factor PDGF-BB,
nerve growth factor NGF, and ciliary neurotrophic factorJournal of Neuroinflammation 2008, 5:32 http://www.jneuroinflammation.com/content/5/1/32
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CNTF) and cytokines (IL-2, IFNγ, TNFα, IL-17, IL-10, IL-
12p40, TGFβ1).
Primary neuronal cultures
Primary CNS cell cultures were prepared from P0 C57BL/
6 pups. Forebrain tissue was removed, dissociated, and
plated on poly-D-lysine coated 18 mm coverslips in 12-
well culture plates. Dissociated brain tissue from litterma-
tes was pooled and plated at a density of 10,000 cell/ml in
Neurobasal media (Gibco) containing 2% B27 supple-
ment (Invitrogen), 1% Penicillin-Streptomycin, 0.5 mM
L-glutamine, and 10 ng/ml NGF (Invitrogen). All experi-
ments were done with the approval of the UCLA Commit-
tee for the Protection of Research Subjects. Cells were
cultured for 10 days with media exchanged every three
days. Then, cells were washed 2× in RPMI and exposed to
1 mM glutamate for 2 h in the presence or absence of
growth factors to test the biological significance of the
combination and dose of growth factors produced by
immune cells. Brightfield microscopy images of TUNEL
(Roche) stained culture slides were obtained at 40× to vis-
ualize neurons. Lactate Dehydrogenase (LDH) is a stable
cytoplasmatic enzyme present in all cells, which is rapidly
released into the cell culture upon damage of the plasma
membrane and its quantification can be used as an objec-
tive measure of cell damage. LDH levels were measured
with a commercially available Cytotoxicity Detection Kit
(Roche) according to manufacturer's instructions at 490
nm on a Multiskan plate reader.
Statistical analysis
For growth factor and cytokine levels, the two baseline
values (month -3 and month 0) were averaged and all val-
ues were log-transformed to achieve a normal distribu-
tion. Changes in growth factor and cytokine levels were
tested using repeated measures ANOVA including all
stimulation conditions and incubation times. In case of a
significant main effect for time in the ANOVA, exploratory
pairwise comparisons were computed to determine signif-
icant increases over baseline. Changes in lymphocyte sub-
populations, DTH recall test results and in vitro
neurotoxicity results were compared using paired t tests.
Pearson correlation coefficients were computed to exam-
ine the association between changes in production of
cytokines and growth factors from baseline to 12-month
of treatment and changes in DTH and clinical outcomes.
A value of p < .05 was considered significant.
Results
Testosterone treatment significantly decreased CD4 T cell
populations (average decrease 17%, p = .03) while
increasing NK cell populations (average increase 64%, p =
.03, Figure 1A). Furthermore, DTH recall responses were
significantly decreased during treatment compared to pre-
treatment values (mean millimeters induration pre-treat-
ment 11.2 ± 2.3; treatment 6.5 ± 1.8, p = .03, Figure 1B).
Regarding effects of testosterone treatment on cytokine
levels, there was a significant decrease in IL-2 production
during the treatment period as compared to pretreatment
baseline (p < .001, Figure 1C). Average decreases in IL-2
were -34% for CD3/CD28 and -58% for PHA stimulation.
In contrast, a significant increase was observed in TGFβ1
levels (p < .0001, Figure 1D) with average increases of
167% for CD3/CD28 and 179% over baseline for PHA
stimulations. No significant changes were observed in
other cytokines (IFNγ, TNFα, IL-10, IL-17, IL-12p40)
tested.
Testosterone treatment significantly increased levels of
growth factors in supernatants of ex vivo stimulated
PBMCs. Specifically, BDNF levels in PBMC supernatants
revealed average increases of over 9 fold at treatment
month 12, as compared to pretreatment baseline, for
CD3/CD28 stimulation, and almost 11 fold for PHA stim-
ulation, (p < .0001, Figure 1E). Highly significant
increases in PDGF-BB production were also observed dur-
ing testosterone treatment, with PDGF-BB levels increas-
ing approximately 3.5 fold during both CD3/CD28 and
PHA stimulation conditions (p < .0001, Figure 1F). No
significant changes were observed in other growth factors
(NGF, CNTF) tested.
Correlation coefficients of cytokine and growth factor
changes with functional and clinical outcomes were com-
puted as an exploratory analysis. The increases in BDNF,
PDGF-BB and TGFβ1 production were significantly corre-
lated (TGFβ1 and BDNF r = .72; TGFβ1 and PDGF-BB, r =
.89; BDNF and PDGF-BB, r = .91). There was a moderate
(but not significant) correlation between TGFβ1 and IL-2
changes (r = .48). Interestingly, there was a positive asso-
ciation between the decrease in CD4+ cells and decreased
responses in the DTH skin test (r = .59) that showed a sta-
tistical trend (p = .07). However, changes in IL-2 did not
significantly correlate with either CD4+ percentage or
DTH. As reported previously [20], testosterone treatment
in our study increased cognitive function as measured by
the Paced Auditory Serial Addition Task (PASAT). Percent
increases in BDNF (r = .74, p = .01) and PDGF-BB (r = .73,
p = .02) from baseline to month 12 of treatment were sig-
nificantly associated with improvements in PASAT testing
during the same time. However, the associations with the
PASAT were driven by the two strongest responders in
growth factors who also had the strongest improvement
in cognitive function and should thus be interpreted with
caution.
Next, we aimed to determine whether levels of BDNF,
PDGF-BB, and TGFβ1, which were induced by in vivo tes-Journal of Neuroinflammation 2008, 5:32 http://www.jneuroinflammation.com/content/5/1/32
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tosterone treatment, were functionally significant. Gluta-
mate excitotoxicity is a widely used model for
neurotoxicity and is thought to contribute to neurodegen-
eration observed in MS [23]. Thus, to test the biological
significance of growth factor levels produced by immune
cells during treatment, neuronal cultures were exposed to
2 h of 1 mM glutamate in the presence or absence of
recombinant growth factors similar to the levels seen in
the best treatment responder at month 12 (2000 pg/ml
TGFβ1, 500 pg/ml BDNF, 100 pg/ml PDGF-BB). Bright-
field microscopy images indicated that addition of growth
factors induced partial protection of axonal integrity in
those cultures (black arrows) and decreased the number
of TUNEL positive cells (white triangles, Figure 2A–C).
LDH quantification showed that the addition of growth
factors during glutamate exposure significantly reduced
LDH release from neuronal cultures, in line with a neuro-
protective effect (p = .04, Figure 2D).
Discussion
Our data suggest that testosterone treatment in MS is asso-
ciated with effects on markers that could play a role in the
inflammatory as well as the neurodegenerative compo-
nent of the disease. A decrease in DTH responses,
decreased IL-2 and increased TGFβ1 production suggest
an anti-inflammatory effect. This was accompanied by a
decrease in CD4+ cells and an increase in NK cells. Based
on our current understanding of MS pathogenesis, CD4+
autoreactive T cells and their differentiation into a Th1
phenotype are crucial events in disease development, and
these cells are probably also important players in the long-
term evolution of the disease [24], while NK cells have
Immunomodulation and growth factor induction by testosterone treatment in 10 male MS patients Figure 1
Immunomodulation and growth factor induction by testosterone treatment in 10 male MS patients. A, Testo-
sterone treatment significantly decreased CD4+ T cell and increased CD16/56+ NK cell percentages. B, Treatment also signif-
icantly decreased delayed type hypersensitivity recall responses. C-F, In addition, treatment significantly decreased IL-2 and 
increased TGFβ1, BDNF and PDGF-BB levels produced by PHA stimulated peripheral blood mononuclear cells (PBMCs) dur-
ing testosterone treatment (months 3–12) compared to baseline (base). Protein levels are expressed as the mean percent 
change compared with the mean from two pretreatment baseline time points. Mean month 12 concentrations were 670.5 ± 
223.4 pg/ml for IL-2, 1552.0+273.3 pg/ml for TGFβ1, 246.1 ± 40.37 pg/ml for BDNF and 42.6 ± 15.6 pg/ml for PDGF-BB, 
respectively.Journal of Neuroinflammation 2008, 5:32 http://www.jneuroinflammation.com/content/5/1/32
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been suggested to play a regulatory role by killing myelin-
specific T cells and immature dendritic cells, promoting
regulatory T cells and enhancing Th2-like responses [25].
Both IL-2 and TGFβ1 have been proposed as treatment
targets in MS. Blocking the IL-2α receptor chain with the
monoclonal antibody daclizumab has been shown to
decrease active lesions on MRI [26]. Interestingly, daclizu-
mab treatment is also accompanied by a decrease in CD4+
T cells, as well as an increase in a subpopulation of NK
cells numbers [27], consistent with our results on altera-
tions in lymphocyte subpopulations during testosterone
treatment.
The role of TGFβ1 in the immune system is complex as it
can affect multiple cell lineages, either promoting or
opposing their differentiation, survival, and proliferation.
However, TGFβ1 appears to be a critical modulator of T
Growth factors reduce neurotoxicity in vitro Figure 2
Growth factors reduce neurotoxicity in vitro. Neuroprotection against glutamate toxicity (1 mM for 2 h) by growth fac-
tors at concentrations similar to those at treatment month 12 in the clinical trial (2000 pg/ml TGFβ1, 500 pg/ml BDNF, 100 pg/
ml PDGF-BB). A-C, Brightfield microscopy images indicate that addition of growth factors during glutamate exposure induced 
partial protection of axonal integrity in those cultures (black arrows) and decreased the number of TUNEL positive cells (white 
triangles), representative images shown from 8 experiments. D, a protective effect was confirmed quantitatively by a significant 
reduction in LDH release. LDH data are shown from 8 independent experiments with wells run in duplicate for each condition.Journal of Neuroinflammation 2008, 5:32 http://www.jneuroinflammation.com/content/5/1/32
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cell-mediated self-reactivity [28] and has been successfully
used to treat EAE [29]. Unfortunately, a clinical trial of
TGFβ2 administration in secondary-progressive MS had
to be stopped due to nephrotoxicity of the recombinant
cytokine [30].
In addition to these immunomodulatory effects, we saw
significant increases in growth factor production by
PBMCs. Neuroprotective effects of testosterone treatment
have been described using both in vitro cultures and in vivo
models. Since testosterone is lipophilic, in vivo effects of
systemic testosterone treatment are thought to be medi-
ated by testosterone crossing the blood brain barrier. In
the CNS, testosterone may bind androgen receptors or
may be converted by aromatase to estrogen, with estrogen
known to have neuroprotective properties [31]. Here, we
describe a novel potential neuroprotective pathway of tes-
tosterone treatment, namely through the induction of
BDNF, PDGF-BB, and TGFβ1 by peripheral blood
immune cells.
This is relevant to MS since neurotrophic factors such as
BDNF have been detected in infiltrating immune cells in
CNS lesions in both experimental autoimmune encepha-
lomyelitis (EAE) [32] and MS [33] and it has been sug-
gested that the immune cell-mediated import of BDNF
and other neurotrophic factors into the central nervous
system has the functional relevance of curbing the detri-
mental effects of inflammation on the surrounding tissue
[19]. Supporting the clinical relevance of this phenome-
non, an increase in BDNF production by PBMCs during
relapse was previously only observed in patients who
achieved full recovery, while patients with incomplete
recovery demonstrated no alterations in BDNF produc-
tion [34]. In addition, a recent study has shown correla-
tions of BDNF production by peripheral immune cells
with MRI-based measures of disease severity. Lower BDNF
production was associated with lower Magnetic Transfer
Ratio (MTR) in normal appearing white matter, suggest-
ing more white matter damage in patients with lower
BDNF production [35].
The neuroprotective effects in vivo and in vitro of BDNF are
well known [36]. PDGF-BB has also been shown to be
neuroprotective in vitro [37] and in vivo [38]. It is interest-
ing to note that TGFβ1, in addition to its anti-inflamma-
tory effects, also protected neurons from glutamate
toxicity in vitro and in vivo [39]. Supporting the protective
potential of growth factors produced by PBMCs in our
study, we found that a combination of recombinant
growth factors at similar concentrations as seen at month
12 of treatment could reduce glutamate-induced neuro-
toxicity in vitro. In this regard, it is intriguing that when the
subjects in our study were assessed for MRI and clinical
outcomes, a slowing in brain atrophy and an increase in
cognitive function was observed during testosterone treat-
ment as compared to baseline [20].
Conclusion
Previously, clinical trials using neurotrophic factors have
been disappointing in neurodegenerative diseases despite
promising results from pre-clinical studies [40]. The nega-
tive results of these clinical trials have highlighted that the
manner and site of administration are of critical impor-
tance. Similarly, anti-inflammatory strategies in MS using
monoclonal antibodies or recombinant cytokines have
been associated with either partial efficacy or significant
toxicities.
In contrast, treatment with physiological levels of testo-
sterone is safe and appears to orchestrate simultaneous
alterations in multiple growth factors and cytokines with
the delivery system being the subjects' own peripheral
blood immune cells. This immunomodulatory and
potential neuroprotective pathway warrants further study
in MS and other neurodegenerative diseases, which con-
tain an inflammatory component, namely Alzheimer's
Disease, Parkinson's disease and spinal cord injury [41].
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